Nevirapine approved by FDA. Food and Drug Administration.
Bowersox
J
J
D000998:Antiviral Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count / Q000187:drug effects; D002986:Clinical Trials as Topic; D016049:Didanosine / Q000627:therapeutic use; D017277:Drug Approval; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D019829:Nevirapine; D011247:Pregnancy; D011725:Pyridines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use
D000998:Antiviral Agents; D011725:Pyridines; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D019829:Nevirapine; D016049:Didanosine